Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants

NCT02302066 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1800

Enrollment

INDUSTRY

Sponsor class

Conditions

Dengue Fever

Interventions

BIOLOGICAL: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
BIOLOGICAL: TDV Placebo

Sponsor

Takeda